Clinical Trial

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial

Study acronym: NC-CHRM

Not Yet Recruiting Phase 3

Summary

Liver disease deaths are rising, but transplants remain scarce in India. With over 100,000 needed annually and only \~2,500 performed, non-transplant options are urgently needed. Regenerative therapy, especially mesenchymal stem cells (MSCs), shows promise but lacks validation, particularly for non-viral ACLF. The proposed NC-CHRM aims to develop and validate MSC-based therapy to promote native liver regeneration and offer a safe, effective, transplant-free treatment.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-07-11.

Trial Details

NCT Number	NCT07075315
Lead Sponsor	Institute of Liver and Biliary Sciences, India Collaborators: Indian Council of Medical Research
Conditions	Acute-On-Chronic Liver Failure
Enrollment	100 participants
Start Date	2028-01
Primary Completion	2031-12 (estimated)
Study Completion	2031-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-17